Patents by Inventor Robin D. G. Cooper

Robin D. G. Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6908996
    Abstract: The present invention relates to novel intermediates for the preparation of 3-methylenecephams of the formula IIA. wherein: R is a carboxylic acid protecting group; R1 is a group of the formula; R10 is C1-C6 alkyl, C1-C6 polyfluoroalkyl, C3-C6 cycloalkyl, adamantyl, phenyl, substituted phenyl, phenyl(C1-C3 alkyl), diphenylmethyl, or substituted phenyl(C1-C3 alkyl), or a group of the formula Z is solid polymer support; and Z1 is one or two groups independently selected from the group consisting of hydrogen, halo, hydroxy, protected hydroxy, nitro, cyano, trifluoromethyl, C1-C4 alkyl, and C1-C4 alkoxy.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: June 21, 2005
    Assignee: Imperial College of London
    Inventors: Robin D. G. Cooper, Anthony G. M. Barrett
  • Publication number: 20040106790
    Abstract: The present invention relates to novel intermediates for the preparation of 3-methylenecephams. More specifically, the present invention relates to the intramolecular cyclization of penicillin sulfoxide derived monocyclic azetidinone as precursors to cephalosporin antibiotics.
    Type: Application
    Filed: November 12, 2003
    Publication date: June 3, 2004
    Inventors: Robin D.G. Cooper, Anthony G.M. Barrett
  • Patent number: 6683176
    Abstract: The present invention relates to novel processes for the preparation of 3-methylenecephams. More specifically, the present invention relates to the intramolecular cyclization of penicillin sulfoxide derived monocyclic azetidinone derivatives with organometallic catalysts of the formula III. MEx(H2O)y  (III) wherein: M is Sc, Y, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Zr, Hf, Th, Nb, Ta, U, Bi, or In; E is O[SO2(C1-C6 polyfluoroalkyl)], N[SO2(C1-C6 polyfluoroalkyl)]2, or C[SO2(C1-C6 polyfluoroalkyl)]3; x is 3; y is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9.
    Type: Grant
    Filed: December 31, 2001
    Date of Patent: January 27, 2004
    Inventors: Robin D. G. Cooper, Anthony G. M. Barrett
  • Patent number: 6610680
    Abstract: This invention provides substituted 2-(azetidinon-1-yl) acetic acid derivatives of Formula II for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: August 26, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Publication number: 20030036650
    Abstract: The present invention relates to novel processes for the preparation of 3-methylenecephams. More specifically, the present invention relates in part to the intramolecular cyclization of penicillin sulfoxide derived monocyclic azetidinone derivatives either thermally or with lanthanide metal salt catalysts.
    Type: Application
    Filed: December 31, 2001
    Publication date: February 20, 2003
    Inventors: Robin D.G. Cooper, Anthony G.M. Barrett
  • Patent number: 6521611
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl) acetic acid derivatives of Formula I for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: February 18, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Patent number: 5977062
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • Patent number: 5843889
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity aginst a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • Patent number: 5840684
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • Patent number: 4772694
    Abstract: 2,5-Disubstituted oxazolidin-4-one-3-ylacetyl chlorides and 1,2,5-substituted imidazolidin-4-one-3-yl-acetyl chlorides function as chiral auxiliary moieties in the asymmetric cycloaddition with aldimines to provide cis-azetidinones. The azetidinones are useful intermediates in the preparation of antibiotics.
    Type: Grant
    Filed: July 24, 1986
    Date of Patent: September 20, 1988
    Assignee: Eli Lilly and Company
    Inventor: Robin D. G. Cooper
  • Patent number: 4734498
    Abstract: 3.beta.-Substituted succinimido)azetidinones represented by the formula ##STR1## wherein R and R.sub.1 are e.g. C.sub.1 -C.sub.5 alkanoyloxy, benzoyloxy, substituted benzoyloxy, or benzyloxy, or one of R and R.sub.1 is hydrogen and the other is as defined above; R.sub.2 is C.sub.1 -C.sub.4 alkoxycarbonyl or an arylvinyl group e.g. styrryl or 2-furylvinyl; and R.sub.3 is e.g. protected-carboxymethyl, or an NH protecting group; are provided via stereoselective cycloaddition of imines with chiral auxiliary 3,4-disubstituted succinimidoacetyl chlorides. The chiral auxiliary e.g., 3S,4S-dibenzoyloxy-and 3S,4S-diacetoxysuccinimidoacetyl chloride, is obtained from tartaric acid via anhydride and imide formation with retention of chirality. The chiral azetidinones obtained are useful intermediates to .beta.-lactam antibacterial compounds.
    Type: Grant
    Filed: July 10, 1986
    Date of Patent: March 29, 1988
    Assignee: Eli Lilly and Company
    Inventor: Robin D. G. Cooper
  • Patent number: 4587053
    Abstract: Oxazolino-azetidinones are prepared by reaction of a phosphorus compound with a 3-exomethylenecepham sulfoxide.
    Type: Grant
    Filed: April 26, 1984
    Date of Patent: May 6, 1986
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, John M. Morin, Jr., Lynn R. Peters
  • Patent number: 4518531
    Abstract: This invention provides a novel allylic chlorination process for inserting a chlorine atom on the saturated methyl group of a 3-methyl-2-but-3-enoate group on the ring nitrogen atom of a 2-azetidinone or thiazolinoazetidinone. The chloro-substituted compounds prepared thereby are novel intermediates used in preparation of cephalosporins.
    Type: Grant
    Filed: November 14, 1983
    Date of Patent: May 21, 1985
    Assignee: Eli Lilly and Company
    Inventor: Robin D. G. Cooper
  • Patent number: 4490370
    Abstract: Naphthylglycyl and tetrahydronaphthylglycyl cephalosporins are potent antibacterial agents and are particularly useful as oral treatments for upper respiratory infections.
    Type: Grant
    Filed: April 12, 1983
    Date of Patent: December 25, 1984
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Larry C. Blaszczak, Jan R. Turner
  • Patent number: 4482553
    Abstract: 7-(2-Benzothienyl)glycylamido cephalosporins have good gram positive activity and favorable pharmacokinetics and are orally effective.
    Type: Grant
    Filed: April 12, 1983
    Date of Patent: November 13, 1984
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bernard J. Graves, Edward R. Lavagnino
  • Patent number: 4468514
    Abstract: Thiazoline azetidinones are converted in good yield to 3-bromo-3-methylcephams by treatment with a bromine source and dimethyl sulfoxide.
    Type: Grant
    Filed: December 17, 1982
    Date of Patent: August 28, 1984
    Assignee: Eli Lilly and Company
    Inventor: Robin D. G. Cooper
  • Patent number: 4430268
    Abstract: This invention provides a novel allylic chlorination process for inserting a chlorine atom on the saturated methyl group of a 3-methyl-2-but-3-enoate group on the ring nitrogen atom of a 2-azetidinone or thiazolinoazetidinone. The chloro-substituted compounds prepared thereby are novel intermediates used in preparation of cephalosporins.
    Type: Grant
    Filed: March 17, 1980
    Date of Patent: February 7, 1984
    Assignee: Eli Lilly and Company
    Inventor: Robin D. G. Cooper
  • Patent number: 4355172
    Abstract: Process for 4-(D-3-amino-3-carboxypropoxy)phenylglyoxylic acid oxime as an amino-protected ester comprising alkylating an amino-protected D-methionine silyl ester with an alkyl or benzyl iodide; cyclizing the alkylsulfonium iodide to an amino-protected D-homoserine lactone; hydrolyzing the lactone to an amino-protected D-homoserine in aqueous base; coupling, to form an ether, the amino-protected D-homoserine as an ester with an ester of 4-hydroxyphenylglyoxylic acid; and forming the oxime of the ether or alternatively coupling the D-homoserine ester with a protected-oxime of an esterified 4-hydroxyphenylglyoxylic acid. The product is useful in preparing the antibiotic FR 1923.
    Type: Grant
    Filed: August 17, 1977
    Date of Patent: October 19, 1982
    Assignee: Eli Lilly and Company
    Inventors: Gary A. Koppel, Robin D. G. Cooper
  • Patent number: 4243587
    Abstract: 1-[.alpha.-(Carboxy)-4-hydroxybenzyl]-3.beta.-aminoazetidin-2-one esters are prepared by converting 2-acyl-3,3-dialkyl-7-oxo-.alpha.-[4-(benzyloxy)phenyl]-4-thia-2,6-diazabic yclo[3.2.0]-heptane-6-acetic acid esters with mercuric acetate in an aqueous organic solvent mixture, e.g., in aqueous methanol, to 7-oxo-3-phenyl-.alpha.-[4-(benzyloxy)phenyl]-4-oxa-2,6-diazabicyclo[3.2.0] hept-2-ene-1-acetic acid esters and the latter are reacted with PCl.sub.5 and pyridine to provide the monocyclic 1-[.alpha.-(carboxy)-4-benzyloxybenzyl]-3.beta.-(.alpha.-chlorobenzylidene -amino)-4-chloroazetidin-2-one esters. Reduction of the dichloro azetidin-2-one with an organo tin hydride and azobisisobutyronitrile affords the deschloro, 1-[.alpha.-(carboxy)-4-benzyloxybenzyl]-3.beta.-benzylideneaminoazetidin-2 -one ester. The latter is hydrolyzed and the 4-benzyloxy group is cleaved via catalytic hydrogenolysis to yield an ester of 1-[.alpha.-(carboxy)-4-hydroxybenzyl]-3.beta.-aminoazetidin-2-one. The 3.beta.
    Type: Grant
    Filed: May 21, 1979
    Date of Patent: January 6, 1981
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Gary A. Koppel, Lawrence J. McShane
  • Patent number: 4226767
    Abstract: 1-[.alpha.-(Carboxy)-4-hydroxybenzyl]-3.beta.-aminoazetidin-2-one esters are prepared by converting 2-acyl-3,3-dialkyl-7-oxo-.alpha.-[4-(benzyloxy)phenyl]-4-thia-2,6-diazabic yclo[3.2.0]heptane-6-acetic acid esters with mercuric acetate in an aqueous organic solvent mixture, e.g., in aqueous methanol, to 7-oxo-3-phenyl-.alpha.-[4-(benzyloxy)phenyl]-4-oxa-2,6-diazabicyclo[3.2.0] hept-2-ene-1-acetic acid esters and the latter are reacted with PCl.sub.5 and pyridine to provide the monocyclic 1-[.alpha.-(carboxy)-4-benzyloxybenzyl]-3.beta.-(.alpha.-chlorobenzylidene amino)-4-chloroazetidin-2-one esters. Reduction of the dichloro azetidin-2-one with an organo tin hydride and azobisisobutyronitrile affords the deschloro, 1-[.alpha.-(carboxy)-4-benzyloxybenzyl]-3.beta.-benzylideneaminoazetidin-2 -one ester. The latter is hydrolyzed and the benzyloxy group is cleaved via catalytic hydrogenolysis to yield an ester of 1-[.alpha.-(carboxy)-4-hydroxybenzyl]-3.beta.-aminoazetidin-2-one. The 3.beta.
    Type: Grant
    Filed: May 21, 1979
    Date of Patent: October 7, 1980
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Gary A. Koppel, Lawrence J. McShane